These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22359398)

  • 41. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.
    Aylward EH; Codori AM; Barta PE; Pearlson GD; Harris GJ; Brandt J
    Arch Neurol; 1996 Dec; 53(12):1293-6. PubMed ID: 8970459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease.
    Gómez-Ansón B; Alegret M; Muñoz E; Sainz A; Monte GC; Tolosa E
    Neurology; 2007 Mar; 68(12):906-10. PubMed ID: 17372125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
    D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multimodal Imaging and Visual Evoked Potentials Reveal Key Structural and Functional Features That Distinguish Symptomatic From Presymptomatic Huntington's Disease Brain.
    Thota SM; Chan KL; Pradhan SS; Nagabushana B; Priyanka GB; Sunil HV; Kanneganti V; Vasoya P; Vinnakote KM; Viswamitra S; Thambisetty M; Kumar D; Tiwari V; Joshy EV; Sivaramakrishnan V
    Neurol India; 2021; 69(5):1247-1258. PubMed ID: 34747792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy.
    Boelmans K; Holst B; Hackius M; Finsterbusch J; Gerloff C; Fiehler J; Münchau A
    Mov Disord; 2012 Mar; 27(3):421-7. PubMed ID: 22290788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regional subcortical shape analysis in premanifest Huntington's disease.
    Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
    Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.
    Coppen EM; Jacobs M; van den Berg-Huysmans AA; van der Grond J; Roos RAC
    Parkinsonism Relat Disord; 2018 Jan; 46():56-61. PubMed ID: 29128164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.
    Wassef SN; Wemmie J; Johnson CP; Johnson H; Paulsen JS; Long JD; Magnotta VA
    Mov Disord; 2015 Jul; 30(8):1107-14. PubMed ID: 25820773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural neuroimaging differentiates vulnerability from disease manifestation in colombian families with Huntington's disease.
    Valdés Hernández MDC; Abu-Hussain J; Qiu X; Priller J; Parra Rodríguez M; Pino M; Báez S; Ibáñez A
    Brain Behav; 2019 Aug; 9(8):e01343. PubMed ID: 31276317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease.
    Jurgens CK; van de Wiel L; van Es AC; Grimbergen YM; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
    J Neurol; 2008 Nov; 255(11):1785-91. PubMed ID: 19156490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain structure in preclinical Huntington's disease: a multi-method approach.
    Wolf RC; Thomann PA; Thomann AK; Vasic N; Wolf ND; Landwehrmeyer GB; Orth M
    Neurodegener Dis; 2013; 12(1):13-22. PubMed ID: 22906775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-related iron deposition in the basal ganglia of controls and Alzheimer disease patients quantified using susceptibility weighted imaging.
    Wang D; Li YY; Luo JH; Li YH
    Arch Gerontol Geriatr; 2014; 59(2):439-49. PubMed ID: 24820446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Widespread subcortical grey matter degeneration in primary lateral sclerosis: a multimodal imaging study with genetic profiling.
    Finegan E; Li Hi Shing S; Chipika RH; Doherty MA; Hengeveld JC; Vajda A; Donaghy C; Pender N; McLaughlin RL; Hardiman O; Bede P
    Neuroimage Clin; 2019; 24():102089. PubMed ID: 31795059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Magnetic Susceptibility Changes in the Basal Ganglia and Brain Stem of Patients with Wilson's Disease: Evaluation with Quantitative Susceptibility Mapping.
    Doganay S; Gumus K; Koc G; Bayram AK; Dogan MS; Arslan D; Gumus H; Gorkem SB; Ciraci S; Serin HI; Coskun A
    Magn Reson Med Sci; 2018 Jan; 17(1):73-79. PubMed ID: 28515413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways.
    Bohanna I; Georgiou-Karistianis N; Egan GF
    Neurobiol Dis; 2011 Jun; 42(3):475-81. PubMed ID: 21382492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural analysis of the basal ganglia in schizophrenia.
    Mamah D; Wang L; Barch D; de Erausquin GA; Gado M; Csernansky JG
    Schizophr Res; 2007 Jan; 89(1-3):59-71. PubMed ID: 17071057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M; Dragunow M; Faull RL
    Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.